Metastatic Melanoma clinical trials

Ablation plus drug therapy for advanced solid tumors

This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.

Mirdametinib for advanced NF1-mutant melanoma

This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.

Belvarafenib with cobimetinib for NRAS-mutant melanoma

This trial tests a combination of two drugs (belvarafenib and cobimetinib) for people with advanced melanoma that has a specific gene change called NRAS. It is for those who have tried other treatments or cannot take them.

T-cell therapy for advanced melanoma

This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.

Standard vs longer radiation for brain metastases

This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.

Testing a new drug plus pembrolizumab versus pembrolizumab alone

This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.

NY-ESO-1 T cells for advanced melanoma and sarcoma

This trial tests a personalized cell therapy using your own immune cells (T cells) that have been modified to recognize a protein called NY-ESO-1, which is found on some melanoma and sarcoma tumors. It may help people whose cancer has progressed after standard treatments.

Interim PET-CT scan to assess anti-PD-1 treatment in melanoma

This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.

Melanoma blood test using a new device (Cytophone)

This trial tests a new, non-invasive device called a liquid biopsy that looks for melanoma cells in your blood. It may help find cancer earlier without needing a needle biopsy.

Freezing tumor plus two immunotherapies for advanced melanoma

This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.

Testing biomarkers in immunotherapy for advanced melanoma

This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.

Long-term safety study for prior RP1, RP2, or RP3 patients

This study checks the long-term safety of patients who have already received RP1, RP2, or RP3 treatment in a previous study. It helps doctors understand any side effects that may appear over time.

Exercise Before Melanoma Immunotherapy Treatment

This study tests whether doing physical exercise right before receiving immunotherapy (two drugs called nivolumab and ipilimumab) helps treat advanced melanoma. The goal is to see if exercise boosts how well these cancer-fighting drugs work in your body.

SBRT radiation plus immunotherapy for limited spread melanoma

This trial tests if combining targeted radiation (SBRT) with standard immunotherapy works better for melanoma that has spread to a few spots in the body (but not the brain). It is for people who have not yet had treatment for their current spread.

Observes people with advanced melanoma in Spain since 2018

This observational study collects information about people with advanced (stage III/IV) melanoma, including cases that are metastatic or cannot be removed by surgery. It may help improve understanding of how melanoma behaves and how it’s being treated across Spain.

Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma

Targeted radiation for melanoma that won’t respond to immunotherapy

This study tests a very focused form of radiation for melanoma that has spread and has stopped responding to PD-1 (and sometimes CTLA-4) immunotherapy. It may help by shrinking progressing spots while keeping the immune treatment going.

Study drug for advanced melanoma and other solid tumors

This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.

A study of PRJ1-3024 for advanced or spreading melanoma

This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.

Drug level monitoring in metastatic melanoma treatment

This trial checks how much of two drugs, encorafenib and binimetinib, remain in your blood while treating advanced melanoma that cannot be removed by surgery. The goal is to learn if drug levels affect how well the treatment works.

Flu vaccine injected into melanoma tumors for stage I-IV

This trial tests whether injecting a flu vaccine directly into melanoma tumors helps shrink them. It is for people with stage I to IV melanoma who have at least one tumor that can be injected.

Study of immune markers in treated metastatic melanoma

This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.

Testing how long to take PD-1 therapy for melanoma

This trial studies whether people with metastatic melanoma should take PD-1 immunotherapy continuously or only for a limited time. It aims to find a schedule that keeps the cancer under control while possibly reducing treatment burden.

Adding ipilimumab to standard melanoma therapy based on ctDNA

This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.